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ABSTRACT 
BACKGROUND: The measurement of gene expression in post-digital rectal examination (DRE) 
urine specimens provides a non-invasive method to determine a patient’s risk of prostate 
cancer. Many currently available assays use whole urine or cell pellets for the analysis of 
prostate cancer-associated genes, although the use of extracellular vesicles (EVs) has also 
recently been of interest. We investigated the expression of prostate-, kidney-, and bladder-
specific transcripts and known prostate cancer biomarkers in urine EVs. 
 
METHODS: Cell pellets and EVs were recovered from post-DRE urine specimens, with the total 
RNA yield and quality determined by Bioanalyzer. The levels of prostate, kidney, and bladder-
associated transcripts in EVs were assessed by TaqMan qPCR and targeted sequencing. 
 
RESULTS: RNA was more consistently recovered from the urine EV specimens, with over 80% 
of the patients demonstrating higher RNA yields in the EV fraction as compared to urine cell 
pellets. The median EV RNA yield of 36.4 ng was significantly higher than the median urine cell 
pellet RNA yield of 4.8 ng. Analysis of the post-DRE urine EVs indicated that prostate-specific 
transcripts were more abundant than kidney- or bladder-specific transcripts. Additionally, 
patients with prostate cancer had significantly higher levels of the prostate cancer-associated 
genes PCA3 and ERG. 
 
CONCLUSIONS: Post-DRE urine EVs are a viable source of prostate-derived RNAs for 
biomarker discovery and prostate cancer status can be distinguished from analysis of these 
specimens. Continued analysis of urine EVs offers the potential discovery of novel biomarkers 
for pre-biopsy prostate cancer detection. 
 
KEY WORDS: Prostate Cancer, Biomarkers, PCA3, ERG  
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INTRODUCTION 
Urinary biomarkers for prostate cancer are highly sought after for their potential to discover and 
track disease progression non-invasively. Currently, the most well-characterized urine 
biomarker for prostate cancer is PCA3, which is a prostate-specific non-coding RNA with 
increased expression in prostate cancer (1,2). When combined with additional clinical 
parameters such as prostate volume, digital rectal examination (DRE) findings, and serum PSA, 
the FDA-approved PCA3 urine assay can improve the detection of prostate cancer (3). 
However, the low sensitivity of the PCA3 assay has encouraged continued investigation to 
identify additional urinary biomarkers (4). This is demonstrated by the pairing of urine assays for 
PCA3 and TMPRSS2:ERG, which improves the sensitivity and specificity over that achieved by 
either assay alone (5-7). However, it is likely that multiplexing of additional genes predictive of 
prostate cancer risk will be necessary before a urine biomarker assay has the level of 
performance to be used in decisions prior to biopsy. 
 
Biomarker discovery in urine has been complicated by the difficulty in obtaining sufficient 
quantities of intact RNA for whole transcriptome analyses. The initial identification of PCA3 and 
TMPRSS2:ERG as prostate cancer biomarkers was based on analysis of prostatectomy tissue, 
while the urine assays were developed from analysis of cell pellets and whole urine (2,8,9). 
Another component of urinary RNAs that have recently been of interest are extracellular 
vesicles (EVs), which encompass microvesicles, apoptotic bodies, and exosomes (10,11). 
Previous investigations of EVs in the context of prostate cancer have demonstrated the 
presence of known prostate cancer-associated transcripts such as KLK3, PCA3, and 
TMPRSS2:ERG within urinary EVs (12-14). A recently developed prostate cancer detection test 
based on the expression of PCA3 and TMPRSS2:ERG in urine EVs has established the 
potential to distinguish patients with and without prostate cancer based on their urine EV 
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transcript expression levels (15). In our current study, we have investigated the RNA content of 
cell pellets and EVs recovered from urine specimens to assess their suitability for transcriptome-
wide analysis and biomarker discovery. 
 
MATERIALS AND METHODS 
Patient Cohort 
Cohort participants were patients at primary care and urology clinics of Emory Healthcare, 
which includes The Emory Clinic, Emory University Hospital, Emory University Hospital 
Midtown, and Emory Saint Joseph’s Hospital. Eligible patients provided informed written 
consent to provide specimens for our research study as part of our EDRN Clinical Validation 
Center cohort and the Winship Cancer Institute Prostate Cancer Tissue Bank. Demographic and 
clinical data were obtained through interviewer-administered questionnaires and Emory 
Healthcare’s medical records database, and are summarized in Table 1. This study was 
conducted with the approval of the institutional review board of Emory University. 
 
Urine Collection and Processing 
For patients undergoing prostate biopsy or radical prostatectomy, all specimens (including 
serum for PSA testing) were collected prior to these procedures. Following an attentive DRE 
performed by a clinical care provider, each patient provided a first-catch urine sample directly 
into 30 mL specimen containers. All urine specimens were transported on crushed ice to the 
laboratory for processing within 4 hours of collection. Urine specimens were centrifuged for 5 
minutes at 700g at 6°C to pellet the cells and the urine supernatant was transferred to a 50mL 
conical tube for further processing. The urine cell pellet was transferred to a non-stick microfuge 
tube, snap frozen, and stored at -80°C. At this point, urine supernatants processed with the 
Post-Freeze Filtration protocol had 0.5M EDTA added to a final concentration of 40mM and 
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were stored at -80°C with the filtration processing to be performed at a later date (generally 
within two weeks of collection), while urine supernatants processed using the Same Day 
Filtration protocol continued through the following procedure on the day of collection 
(Supplementary Figure 1A). Urine supernatants were centrifuged at 2000g for 5 minutes at 
room temperature to remove cell debris before being filtered through a 0.8 µm syringe filter. The 
filtered supernatant specimens were then centrifuged through an Amicon Ultra-15 Centrifugal 
Filter Unit with Ultracel-100 membrane at 3400g at 21°C for 10 minutes. The flow-through was 
discarded and the centrifugation step repeated until the entire sample had been passed through 
the filter unit. The filter unit was then washed with 15 mL of PBS and centrifugation at 3400g at 
21°C for 10 minutes. The concentrated sample collected in the filter unit, which contained the 
EVs, was transferred to a non-stick microfuge tube and the volume was made up to 200 μL with 
PBS if required. The filter unit was rinsed with 700 μL of RLT Buffer with DTT (RLT/DTT 
prepared according to instructions in the Qiagen RNeasy Micro Kit) and this was also added to 
the microfuge tube containing the EVs. The total recovered volume of EV sample plus RLT/DTT 
solution was measured and 100% ethanol was added to a final concentration of 35%. The 
samples were then vortexed to disrupt the vesicles and either stored at -80°C if RNA extraction 
was to be performed at a later date (samples processed with the Same Day Filtration protocol; 
Supplementary Figure 1A), or they were immediately carried through to the RNA isolation 
protocol below (samples processed with the Post-Freeze Filtration protocol; Supplementary 
Figure 1A). 
 
RNA Isolation 
Total EV RNA was extracted using the Qiagen RNeasy Micro Kit and total urine cell pellet RNA 
was extracted using the Qiagen AllPrep DNA/RNA Micro Kit. Each of these methods were 
carried out according to manufacturer’s instructions, and included an on-column DNase I 
treatment. To elute the RNA, the spin column was transferred to a non-stick microfuge tube 
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containing 1 μL of GlycoBlue solution (1 μg/μL), and then 20 μL of RNase-free water (pre-
warmed to 45°C) was added directly to the spin column membrane. Following incubation at 
room temperature for 5 minutes, the spin column was centrifuged for 1 minute at 20000g. The 
Agilent RNA Pico Kit and Bioanalyzer were used to determine RNA concentration and quality. 
 
Transmission Electron Microscopy (TEM) 
A 5 μL aliquot of each urine EV sample was deposited onto a 400 mesh carbon coated copper 
grid that had been glow-discharged for 20 seconds.  Grids containing EV samples were placed 
in a covered glass dish to allow vesicles to settle.  After 5 minutes, each grid was washed by 
briefly touching the sample side to three drops of de-ionized water.  Excess water was then 
removed from the grid with filter paper, and the sample was stained with 1% phosphotungstic 
acid (pH 6.5) for 20 seconds. Phosphotungstic acid was removed with filter paper and the 
samples were left to air dry for 10 minutes.  Imaging was done on a JEOL JEM-1400 
transmission electron microscope equipped with a 2k × 2k Gatan US1000 CCD camera. 
 
Gene Expression Analysis by TaqMan qPCR 
The transcripts of interest were analyzed using TaqMan Gene Expression Assays (details 
included in Supplementary Table 1). Up to 20 ng of RNA (average: 13.1 ng, range: 4.6-20 ng) 
was converted into cDNA with the NuGEN Ovation PicoSL WTA System V2, and the reaction 
product was purified with the Qiagen MinElute Reaction Cleanup Kit. The cDNA yield for each 
sample was measured on a NanoDrop using the ssDNA setting, which indicated an average 
cDNA yield of 4.8 μg (range: 3.2-6.5 μg). TaqMan Gene Expression Assays were set up using 
TaqMan Universal Master Mix II (without Uracil N-Glycosylase) with 20 ng of cDNA/reaction. 
Data was normalized to RAB7A. Cycle threshold values for non-detected assays were set to 40. 
 
Measurement of Gene Expression by Precise Assay 
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Gene expression was also assessed using the multiplex Precise Assay technology developed 
by Cellular Research. In this method, each RNA transcript is labeled with a unique molecular 
index during reverse transcription allowing measurement of the number of transcripts in the 
original starting material (16,17). Each reaction was performed using 1 ng of RNA with each 
specimen run in triplicate. Amplification was conducted for a targeted set of genes according to 
manufacturer instructions, which includes 15 cycles of first-round amplification followed by 12 
cycles of nested, second-round, amplification (approximately 300 different genes were targeted 
in this analysis). The libraries were sequenced at the HudsonAlpha Genomic Services Lab to 
produce 150 bases of paired-end reads with an average of over 300000 reads mapped per 
sample. The 150 base sequence length is sufficient to determine gene identity from the initial 
read, with sample and molecular index information derived from the paired read. Sequence data 
was processed using the Cellular Research Precise Analysis Pipeline v2.4 on the Seven 
Bridges Genomics platform and molecular index counts were used to perform expression 
analysis. Molecular index counts were retained if the average over the three technical replicates 
was at least 5, and the data was normalized to the reference gene, RAB7A. When fewer than 5 
molecular index counts were detected, the relative expression was set to 0. 
 
Statistical Analysis 
Descriptive statistics of variables focused on medians, interquartile ranges (IQR), frequencies, 
and proportions as appropriate. Significance was determined using Wilcoxon rank sum test, 
Welch’s two-sample t-test, or ANOVA, with all analysis and plotting conducted in R v3.2. The 
boxplots show the median and IQR, with 1.5x IQR represented by whiskers and outliers marked 
with dot points. 
 
RESULTS 
Post-DRE Urine Extracellular Vesicles Contain More RNA than Urine Cell Pellets 
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We began our assessment of urinary RNAs by characterizing the yield and quality of RNA 
isolated from the cell pellet and EV fractions of post-DRE urine collected from 105 patients. For 
the majority of patients (86 patients, 81.9%), more RNA was recovered from the EVs than from 
the cell pellet (Figure 1A). RNA yields from the cell pellets were typically very low, with the 
majority of the cell pellets producing less than 10 ng of RNA (74 specimens, 70.5%), which 
included 23 specimens (21.9%) where less than 1 ng of RNA was recovered. In contrast, very 
few of the EV specimens had less than 1 ng of RNA (2 specimens, 1.9%), and only 24 (22.9%) 
produced less than 10 ng of RNA. 
 
Overall, the median EV RNA yield of 36.4 ng (IQR: 11.6-80.9 ng) was significantly higher than 
the median cell pellet RNA yield of 4.8 ng (IQR: 1.3-13.5 ng; Wilcoxon rank sum test p < 0.001; 
Figure 1B). RNA quality as measured by RNA Integrity Number (RIN) was also generally higher 
for the EV specimens, as the majority of EV specimens (89 specimens, 84.8%), but fewer than 
half of the cell pellet specimens (46 specimens, 43.8%) had a RIN ≥5 (Figure 1C). The samples 
with low RINs included 17 cell pellets and 3 EV specimens that were too low in concentration or 
quality for a RIN to be determined (Figure 1C). The Bioanalyzer profiles for EV and cell pellet 
RNAs both demonstrated the presence of 18S and 28S rRNAs, confirming that the detected 
RNA was not from bacterial contaminants in the urine (Supplementary Figure 2). After focusing 
our attention on the EV specimens, we investigated the relationship between RNA yield and 
cancer status, finding no significant differences in EV RNA yields for patients with no evidence 
of disease, or low risk, intermediate risk, or high risk prostate cancer (ANOVA p = 0.275; Figure 
1D). Characterization of the EV fraction of post-DRE urine by TEM demonstrated the presence 
of larger microvesicles (~200 nm) and smaller particles likely to be exosomes (30-100 nm, 
Figure 2). 
 
RNA from Extracellular Vesicles Can Still be Recovered After Freezing 
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To improve the feasibility of EV assays for clinical sites without on-site laboratory facilities we 
investigated whether EVs could be recovered from frozen urine supernatants, allowing the more 
time-consuming filtration step to be carried out later. For 82 of the specimens, filtration was 
performed on the same day as collection (Same Day Filtration), while 23 of the specimens were 
frozen after removing the cell pellet and EV RNA isolation was carried out separately (Post-
Freeze Filtration; Supplementary Figure 1A). The median RNA yield was 36.1 ng (IQR: 11.6-
79.3 ng) for specimens processed with the Same Day Filtration protocol, which was not 
significantly different from the 47.0 ng (IQR: 12.6-95.2 ng) median EV RNA yield from the Post-
Freeze Filtration protocol (Wilcoxon rank sum test p = 0.667; Supplementary Figure 1B). For the 
majority of samples, the time between freezing and EV/RNA isolation was less than one week. 
 
Extracellular Vesicle RNA Yields are Significantly Lower in Urine Collected Without DRE 
We also determined that the application of a DRE immediately prior to urine collection was 
necessary for the recovery of sufficient EV RNA. Urine collections from 36 consecutive patients 
were randomly performed either with or without a prior DRE. The median EV RNA yield from 
post-DRE urine was 36.9 ng (IQR: 11.6-79.3 ng), which was similar to that observed in the 
larger cohort described above (Supplementary Figure 3). However, urine collected without a 
DRE had a significantly lower median EV RNA yield of 3.1 ng (IQR: 1.7-4.0 ng; Wilcoxon rank 
sum test p < 0.001; Supplementary Figure 3). 
 
Post-DRE Urinary Extracellular Vesicles are Enriched for Prostate-Specific Transcripts 
As urine may contain molecules originating from tissues throughout the genitourinary system, 
we used TaqMan qPCR to assess genes considered to have prostate-, kidney-, or bladder-
specific expression to better understand the relative contribution of each of these tissues. These 
genes were selected based on a previous study that performed whole transcriptome RNA 
sequencing on EVs from urine collected without a prior DRE to investigate a range of transcripts 
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representing different regions of the kidney and bladder (18). Overall, the prostate-specific 
transcripts had much higher expression levels than any of the kidney- or bladder-specific 
transcripts we assessed. The highest expressed transcript was HOXB13 at a median 
normalized expression level of 0.058 (IQR: 0.042-0.076), followed by KLK2 (median normalized 
expression of 0.025, IQR: 0.019-0.035), and KLK3 (median normalized expression of 0.016, 
IQR: 0.009-0.025; Figure 3). The lowest expressed prostate-specific transcript we assessed 
was TRPM8, which had a median normalized expression level of 0.005 (IQR: 0.004-0.007). In 
contrast, the highest expressed of the kidney- and bladder-specific transcripts, UPK2, had a 
median normalized expression of 0.002 (IQR: 0.001-0.004; Figure 3). This is over 2-fold lower 
than the level observed for TRPM8, and almost 30 times lower than HOXB13. The values for all 
other kidney- and bladder-specific transcripts we assessed were less than 0.001, with a number 
of them not detectable in all 60 samples (AQP2, CUBN, NPHS2, and SLC34A1 were detected 
in 52, 59, 40, and 58 specimens, respectively). 
 
Known Prostate Cancer Biomarkers Are Detectable in Post-DRE Urine Vesicles 
To determine whether gene expression in post-DRE urine EVs differed between patients with 
and without prostate cancer, we investigated the expression of the known prostate cancer-
associated genes KLK3, PCA3, and ERG with TaqMan qPCR. No difference in KLK3 
expression was observed when comparing patients with no evidence of disease (N.E.D.) to 
patients with low risk (GS6) or aggressive (GS7+) prostate cancer (ANOVA p = 0.672; Figure 
4A). PCA3 was also robustly detected in all patients, with significantly higher levels observed in 
patients with prostate cancer. Mean expression of PCA3 was 4.5-fold and 4.8-fold higher for 
patients with GS6 and GS7+ prostate cancer, respectively, as compared to patients with no 
evidence of disease (Welch’s two-sample t-test p = 0.002 and p < 0.001; Figure 4B). However, 
mean PCA3 expression was not significantly different when comparing the GS6 and GS7+ 
groups (1.1-fold, Welch’s two-sample t-test p = 0.831; Figure 4B). Patients with GS7+ prostate 
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cancer also had significantly higher levels of ERG as compared to patients with no evidence of 
disease (10.5-fold, Welch’s two-sample t-test p = 0.027; Figure 4C). Patients with GS6 prostate 
cancer showed a 6.4-fold increase over patients with no evidence of disease, although this was 
not significant (Welch’s two-sample t-test p = 0.116). There was also no significant difference 
between the GS6 and GS7+ patient groups (1.6-fold, Welch’s two-sample t-test p = 0.433; 
Figure 4C). 
 
Prostate-Specific Transcripts Are Also Detectable Via Multiplex Precise Assay 
After performing the individual assays, we were interested in investigating a novel method for 
multiplex transcript analysis that could expand our ability to discover and detect urinary RNAs. 
The Precise Assay technology encodes each RNA transcript with a unique molecular index 
during reverse transcription before any amplification has occurred. Analysis of these molecular 
index sequences is intended to distinguish the number of molecules in the starting material from 
PCR duplicates arising during amplification (16,17). A comparison of the raw data generated by 
the individual TaqMan qPCR assays and the multiplex Precise Assay is provided in 
Supplementary Figure 4. 
 
In agreement with the TaqMan qPCR analysis, the multiplex Precise Assay demonstrated that 
the prostate-specific transcripts, KLK3, KLK2, HOXB13, and TRPM8, were more abundantly 
expressed than the kidney- or bladder-specific transcripts (Figure 5A). However, the highest 
expressed transcript detected in the Precise Assay was KLK3, at approximately 10-fold higher 
abundance than the next highest expressed transcript, KLK2. In contrast, KLK3 and KLK2 had 
very similar expression levels when assessed by TaqMan qPCR, where the highest expressed 
transcript was HOXB13 (Figure 3). Analysis of the read-to-molecule ratio of the prostate-
associated genes and RAB7A indicated that most of the transcripts were amplified at similar 
levels, with approximately 10 sequence reads for each molecule. However, HOXB13 showed a 
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relatively low ratio (3.8 reads/molecule) suggesting that amplification of this transcript in the 
Precise Assay was less efficient than the other transcripts (Figure 5D). The Precise Assay also 
demonstrated very low expression of the kidney- and bladder-specific transcripts, with none 
being detected in all 60 samples. In particular, NPHS2, PTH1R, and SLC34A1 were not 
detected in any sample and are shown with a normalized expression of zero (Figure 5A). 
 
When we focused our analysis on the prostate cancer-associated genes, the largest difference 
between the TaqMan and Precise approaches was that ERG could not be detected by Precise 
Assay. However, the Precise Assay demonstrated similar patterns of expression to TaqMan 
qPCRs when assessing differences in KLK3 and PCA3 amongst each of the patient groups. 
While KLK3 was very highly expressed, there was no significant difference between patients 
with GS6 or GS7+ prostate cancer when compared to patients with no evidence of disease 
(ANOVA p = 0.864; Figure 5B). The rate of detection for PCA3 was lower by Precise Assay, 
where it was only detected in 50% of the patients with no evidence of disease (6 out of 12), 71% 
of the patients with GS6 prostate cancer (10 out of 14), and 77% of patients with GS7+ prostate 
cancer (20 out of 26). Mean expression of PCA3 was 2.5-fold and 3.3-fold higher for patients 
with GS6 and GS7+ prostate cancer, respectively, as compared to patients with no evidence of 
disease, although only the increase in the GS7+ group was statistically significant (Welch’s two-
sample t-test p = 0.052 and p = 0.003; Figure 5C). As observed with the TaqMan qPCR assay, 
there was no significant difference in PCA3 expression between patients with GS6 and GS7+ 
prostate cancer (1.4-fold, Welch’s two-sample t-test p = 0.327; Figure 5C). 
 
DISCUSSION 
While urine assays for PCA3 and TMPRSS2:ERG have provided more options and improved 
detection for men at risk of prostate cancer, the discovery of additional urinary biomarkers is 
needed to improve the sensitivity and specificity of this approach before it could have a 
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meaningful role in pre-biopsy decision-making. This study was focused on understanding how to 
recover RNAs from post-DRE urine for comprehensive discovery studies. Our initial findings 
established that urine EVs had significantly higher quantities of intact RNA than urine cell 
pellets, regardless of the cancer-status of the patients. In particular, usable amounts of RNA 
were most reliably recovered from the EV fraction of post-DRE urine, indicating that urine EVs 
are more suitable for further expression analyses. Additionally, during our optimization of the 
urine EV isolation protocol, we found the yield of EV RNA to be unaffected following frozen 
storage of urine supernatants, suggesting that urine EVs are stable at low storage temperatures 
and during freeze-thaw. This is further supported by previous observations that exosomes and 
microvesicles remain intact throughout repeated freeze-thaw cycles (19-21). This demonstrates 
the potential for implementation of urine EV-based assays at clinics lacking on-site laboratory 
facilities, and the possibility of isolating urine EVs from archived urine supernatants. 
 
Our analysis of EV RNA also demonstrated the high quality of the RNA, which included the 18S 
and 28S rRNA peaks. Previous studies investigating RNA recovered from urine exosomes and 
vesicles have not established a consensus on the expected EV RNA profile. While many have 
shown that urine EVs can contain the full complement of RNAs, with small RNAs, mRNAs, and 
rRNAs all present (18,22,23), a number of other studies have only observed small RNAs in 
urine EVs, with rRNAs completely absent (24,25) In one of these studies, rRNAs that were 
originally assumed to be eukaryotic were actually found to be 16S and 23S prokaryotic rRNA 
peaks from contaminating bacteria in the urine (25). We have confirmed that the rRNAs in our 
post-DRE urine EV specimens are eukaryotic, indicating that mixed urine EV populations can 
contain the full complement of RNAs and that contaminating prokaryotic species are unlikely to 
have contributed significantly to our observed RNA yields. However, it would not be appropriate 
to use our results to demonstrate the relative presence of small RNAs to larger RNA species as 
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the RNA extraction method we have used is not intended for the recovery of small RNAs (< 200 
nucleotides). 
 
One of the complications of urine-based biomarkers is the possibility for genes expressed by 
other tissues in the genitourinary tract to contribute to the detected signal. However, we found 
prostate-specific genes to be present at much higher levels than any of the kidney- or bladder-
specific genes indicating that urinary EVs are enriched for prostate-specific RNAs. The urine in 
this study was collected following a DRE, which may have increased the presence of prostate-
derived cells/vesicles/molecules in the urine. This is supported by a number of previous studies 
that have demonstrated increased expression of prostate cancer biomarkers, such as KLK3, 
PCA3, and TMPRSS2:ERG, in urine following a DRE (12,13). However, a similar abundance of 
prostate-associated RNAs has been observed in exosomes isolated from healthy donor urine 
collected without a prior DRE (18), suggesting that other factors other than the DRE may be 
responsible for this effect. Another recent study found significantly increased levels of the 
exosomal markers CD9 and CD63 in urine collected following a DRE as compared to urine 
collected without a DRE, while there were significantly decreased levels of these exosomal 
markers in urine collected from patients that had undergone a prostatectomy or from women 
(26). This indicates that the prostate may contribute a large proportion of the vesicles found in 
urine of men, and that an enrichment of prostate-derived transcripts would be expected. Further 
characterization with tissue-specific surface markers could provide further insight into the origins 
of urinary EVs. This would be of particular importance for biomarker discovery in kidney or 
bladder conditions, where an abundance of prostate-derived EVs may cause urine EV 
biomarker assays to perform very differently for men and women. 
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Having established post-DRE urine EVs as a viable source of prostate-derived RNAs, we next 
investigated the detection of prostate cancer-associated transcripts. PCA3 and ERG expression 
was significantly higher in patients with prostate cancer as compared to those without prostate 
cancer. This is in agreement with previous studies, which have demonstrated that these genes 
are expressed at higher levels in the urine vesicles of patients with prostate cancer and 
substantiates the rationale for using post-DRE urine EV RNA as a biomarker source (15,27). 
KLK3 was very highly expressed in urine EVs from all patients, but showed no significant 
difference between the three patient groups. Given that KLK3 is not specific for cancer and is 
currently used as a normalizer gene for the PCA3 and TMPRSS2:ERG urine assays (3), this 
consistent expression across all of the patient groups fits with its expected performance and 
supports the validity of studying urine EVs. 
 
Our experience with the Precise Assay indicated that there was some loss of detection 
sensitivity when using the multiplex platform, as opposed to the robust detection in all or most of 
the specimens when using individual TaqMan qPCR assays. In particular, none of the kidney 
and bladder transcripts could be detected in all 60 specimens when using the Precise Assay, 
and a number of the transcripts (NPHS2, PTH1R, and SLC34A1) were not detected in any 
sample with this method. The number of specimens with detectable PCA3 and ERG was also 
reduced when using the Precise Assay. There are a number of possible reasons for the 
differences in sensitivity of the two methods, although a large contributing factor may be the low 
RNA input (1 ng) used in the Precise Assay. While being able to use less RNA is appealing due 
to ensuring that more specimens are able to meet the required input, it does introduce 
complications when trying to detect transcripts of lower abundance, with lack of detection and 
high variability between replicates becoming more likely. Another factor that may have 
influenced the comparative performance of the two assays are the relative efficiencies of the 
reverse transcription and amplification for each method. This may be best demonstrated by the 
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difference in the apparent abundance of HOXB13, which was less efficiently amplified by the 
Precise Assay than the other prostate-specific transcripts. Future iterations of this assay will 
need to be carefully designed to ensure that all transcripts amplified concurrently can be 
adequately and accurately detected. 
 
Although this study was limited to known urine biomarkers while we focused on characterizing 
the RNA and investigating the implementation of this technique, the Precise Assay technology 
that we have used is capable of detecting up to 150 genes simultaneously. Prognostic 
biomarker panels assessed in biopsy or radical prostatectomy tissue generally assess 20-30 
genes to create an overall risk score (28-31) and the combination of the PCA3 and 
TMPRSS2:ERG urine assays demonstrates that the performance of urine biomarker panels can 
also be improved with the addition of more genes (5-7). This proof of principle study has better 
characterized the RNA recovered from post-DRE urine EVs, and demonstrated the feasibility of 
performing multiplex gene expression analyses in this specimen type. We are currently 
expanding our analysis to include additional prostate cancer-associated genes that have not 
previously been investigated in urine. The ability to recover sufficient urinary RNA to conduct 
comprehensive gene expression analysis is likely to accelerate the development of urine 
biomarker panels for the accurate determination of prostate cancer risk prior to biopsy. 
 
CONCLUSIONS 
 We have demonstrated that post-DRE urine EVs are a more reliable source of RNA than urine 
cell pellets, that prostate-specific transcripts are enriched in these EVs, and that the current 
urinary prostate cancer biomarkers, PCA3 and ERG, are present at significantly higher levels in 
the urine EVs of prostate cancer patients. These findings indicate that prostate cancer status is 
reflected in urinary EVs, and that continued analysis of urine EVs offers the potential to discover 
additional biomarkers for prostate cancer detection. 
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FIGURE LEGENDS 
 
Figure 1. RNA yield from the pellet and extracellular vesicle (EV) fraction of post-DRE 
urine. (A) Urine was collected following a DRE and processed to isolate the cell pellet and EV 
fraction. For each sample, the amount of RNA extracted is represented as a stacked bar, with 
the amount isolated from the EVs shown in dark gray while the amount of RNA isolated from the 
cell pellet is shown in light gray (n = 105). The y-axis has been split to improve visualization of 
the low yield samples. (B) Summary data of the data in A is represented with boxplots (outliers 
are not shown). The RNA yield was significantly higher in the EVs (p < 0.001). (C) The 
frequency of RNA quality is shown for EVs (upper plot) and cell pellets (lower plot). The RIN 
scale goes from 1 to 10, with samples of particularly low quality or concentration unable to have 
RINs determined (shown as N/A). Representative Bioanalyzer plots are shown in 
Supplementary Figure 2. (D) The yield of EV RNA was not significantly different amongst 
patients with no evidence of disease (N.E.D.) or various levels of prostate cancer risk (p = 
0.275; n = 34, 28, 36, and 11; one outlier in the GS7 group at 506 ng not shown). 
 
Figure 2. Analysis of urinary extracellular vesicles (EVs) by TEM. The EV fractions 
recovered from two different patients were negatively-stained and imaged by TEM. The 
observed particles include larger microvesicles (arrows) as well as smaller vesicles likely to be 
exosomes (arrowheads; scale bar on both images represents 200 nm). 
 
Figure 3. Prostate-specific genes are enriched in post-DRE urine EVs. The expression of 
various prostate-, kidney-, or bladder-specific transcripts were measured by TaqMan qPCR and 
are shown relative to the expression of RAB7A (n = 60). The boxplots for AQP2, CUBN, 
NPHS2, and SLC34A1 include data for samples where no amplification was observed and the 
cycle threshold was set to 40 (8, 1, 20, and 2 samples, respectively). 
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Figure 4. Prostate cancer-associated RNAs are detectable and informative in post-DRE 
urine EVs. The expression levels of (A) KLK3, (B) PCA3, and (C) ERG were measured by 
TaqMan qPCR assay and normalized to RAB7A. The data is shown for patients with no 
evidence of disease (N.E.D., n = 12), Gleason score 6 prostate cancer (GS6, n = 14), or 
Gleason score ≥7 prostate cancer (GS7+, n = 26). The ERG plot includes data for 9 samples 
where no amplification was observed and the cycle threshold was set to 40 (2, 2, and 5 samples 
for the N.E.D., GS6, and GS7+ groups, respectively). In comparison to the N.E.D. group, the 
GS6 and GS7+ groups both had significantly higher expression of PCA3 (p = 0.002 and p < 
0.001, respectively), while only the GS7+ group had significantly higher expression of ERG (p = 
0.027). There was no significant difference in KLK3 expression between the any of the groups 
(p = 0.672). 
 
Figure 5. Precise Assay measurement of transcripts also shows enrichment of prostate-
specific and prostate cancer-associated transcripts. (A) The same prostate-, kidney-, and 
bladder-specific transcripts shown in Figure 3 were assessed by Precise Assay and normalized 
to RAB7A (n = 60). KLK3 is shown on a different scale because it was present at much higher 
levels than the other transcripts. The boxplots for AQP2, CUBN, NPHS2, PTH1R, SLC12A1, 
SLC12A3, SLC34A1, UPK1B, and UPK2 include data for samples where no transcripts were 
detected and the normalized expression was set to 0 (17, 7, 60, 60, 15, 54, 60, 17, and 22 
samples, respectively). Transcripts for (B) KLK3 and (C) PCA3 were measured by Precise 
Assay and normalized to RAB7A (n = 12, 14, and 26 for the N.E.D., GS6, and GS7+ groups, 
respectively). The PCA3 plot includes data for 14 samples where no transcripts were detected 
and normalized expression was set to 0 (6, 4, and 6 samples for the N.E.D., GS6, and GS7+ 
groups, respectively). GS7+ patients had significantly higher expression of PCA3 as compared 
to the N.E.D. group (p = 0.003). (D) The ratio of sequence reads to molecular index count is 
 23 
shown for all of the prostate-associated genes and the normalizer RAB7A (means and 95% 
confidence intervals shown). 
 
